Does MassHealth Cover Zepbound? 2026 Rules and Who Qualifies

MassHealth does cover Zepbound right now, but that coverage ends for most members on July 1, 2026. After that date, MassHealth will no longer pay for Zepbound or other medications prescribed solely for weight loss. Coverage continues only for members who have specific qualifying conditions beyond obesity, and those members will generally need to try Wegovy first.

Coverage Through June 30, 2026

Zepbound is a preferred drug on the MassHealth Drug List through the end of June 2026. It requires prior authorization and is limited to four pens per 28 days.¹

To be approved, your prescriber has to document the diagnosis, confirm you are at least 18, record a recent baseline weight, and show you have been counseled on diet and physical activity. The BMI threshold depends on your situation. A BMI of 35 or higher qualifies on its own. Lower BMIs (27 or 30) require a weight-related condition such as type 2 diabetes, a prior heart attack, hypertension, or sleep apnea.¹

Since October 2025, members who have both diabetes and obesity face an extra step. They must first try Mounjaro, which contains the same active ingredient as Zepbound but is approved for diabetes, or their prescriber must document why Mounjaro is not appropriate.²

For renewal, you have to show continued clinical benefit: at least 5% weight loss from baseline, improvement in a secondary measure like blood pressure or blood sugar, or documented improvement in sleep apnea symptoms. Weight has to be recorded within the last 90 days.¹

What Changes on July 1, 2026

Starting July 1, 2026, MassHealth will no longer pay for drugs used solely to treat obesity or overweight. The change hits a long list of anti-obesity medications, not just Zepbound. Wegovy, Saxenda, Contrave, Qsymia, Xenical, and several others are all being dropped for their weight-loss indications.³ Zepbound itself is losing its preferred status and moving to non-preferred.⁴

For members who still qualify under one of the remaining medical indications, Wegovy becomes the sole preferred drug. Getting Zepbound after July 1 will require first trying Wegovy and showing it didn’t work or wasn’t appropriate.⁴ For members aged 12 to 21 who are new to GLP-1 therapy, step therapy is more involved: they must also complete a trial with phentermine before moving to a GLP-1 medication.⁵

Conditions That Still Qualify After July 1

Losing the obesity indication does not close every door. If your prescriber can document one of the following, MassHealth will still consider covering a GLP-1 drug through a new prior authorization:

Established cardiovascular disease (prior heart attack, stroke, symptomatic peripheral arterial disease, or prior revascularization) with a BMI of 27 or higher, to reduce major adverse cardiovascular events.⁶
Moderate to severe obstructive sleep apnea with a BMI of 30 or higher.⁶
Non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced fibrosis. No BMI requirement applies.⁶
Members under 21, whose requests will be reviewed for medical necessity under federal Early and Periodic Screening, Diagnostic, and Treatment rules.³
Diabetes or prediabetes. These members should be switched to a diabetes-indicated GLP-1 such as Mounjaro or Ozempic, which remain covered under separate criteria.³

If You Already Have an Approved Authorization

Members with an active Zepbound prior authorization can continue filling prescriptions through June 30, 2026.⁵ Authorizations submitted before February 17, 2026, are being end-dated as of June 30, and affected members will receive a letter.³

If your existing Zepbound authorization was tied to a qualifying medical condition and runs past July 2, MassHealth will replace it with an approved authorization for Wegovy for the remainder of the original period. Your prescriber will need to send a new prescription for Wegovy to make the switch.⁴

If Your Prior Authorization Is Denied

You have options. Your prescriber can submit a new prior authorization with additional evidence, including citations to peer-reviewed medical literature explaining why the standard step therapy requirements are medically inappropriate for you.⁷

If the denial comes through a MassHealth managed care plan, you have to exhaust the plan’s internal appeals first. After that, you’re entitled to a fair hearing under 130 CMR 610.000. If the hearing also denies your claim, you can appeal to Superior Court in your county of residence or in Suffolk County within 30 days.⁸

Paying for Zepbound Without MassHealth

The manufacturer savings routes most patients rely on are closed to MassHealth members. Federal law prohibits the use of manufacturer savings cards for drugs covered by government programs, and Eli Lilly’s Zepbound savings card explicitly excludes anyone enrolled in Medicaid, Medicare, or other government-funded insurance.⁹ The Lilly Cares patient assistance program does not currently include Zepbound.¹⁰

Lilly does sell Zepbound vials directly through its LillyDirect platform on a cash-pay basis, at prices ranging from $349 to $699 per month depending on the dose. These vials require self-injection with a syringe rather than the autoinjector pens used with the standard prescription, and health insurance cannot be applied.¹¹

Other Obesity Treatments MassHealth Still Covers

Bariatric surgery remains a covered benefit, subject to prior authorization and the medical necessity criteria in MassHealth’s clinical guidelines. If you’re in a managed care plan, check your plan’s medical policy, which may differ from the general MassHealth standards.¹² Medical nutrition therapy is also covered, including nutritional diagnostic services and counseling for medical conditions, when provided by licensed dietitians, nutritionists, or other qualified practitioners.¹³

Members currently working with the state’s Vida Health program will keep access to health coaching, nutrition support, and lifestyle guidance after July 1, 2026. Vida will no longer prescribe anti-obesity medications or schedule visits with its physicians or nurse practitioners for that purpose, and members who need continued medical care will be directed to their existing prescriber or to the GIC network directory.⁶

1
MassHealth Drug List. Therapeutic Class Detail – Zepbound
2
Mass.gov. MassHealth Pharmacy Facts, Issue 12
3
Point32Health. MassHealth Coverage Change – Anti-Obesity Medications
4
Mass.gov. MassHealth Pharmacy Facts, Issue 7
5
Mass General Brigham Health Plan. Formulary Updates May 2026 Newsletter – Medicaid
6
Mass.gov. June Update on Vida Health Program and GLP-1 Coverage
7
Mass.gov. MassHealth Appeal Decision 2412410
8
Mass.gov. MassHealth Appeal Decision 2511025
9
Eli Lilly. Zepbound Savings
10
NiceRx. Zepbound Patient Assistance Program
11
NPR. Zepbound Eli Lilly Direct Cost
12
Mass.gov. MassHealth Guidelines for Medical Necessity Determination for Bariatric Surgery
13
Cornell Law Institute. 130 CMR 405.475 – Medical Nutrition Therapy